The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Unmet needs that remain for patients with myeloma in the UK
In this video, Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, highlights three significant unmet needs that remain for patients with multiple myeloma (MM) in the United Kingdom. These include delayed diagnosis, the need to replace thalidomide with lenalidomide in treatment regimens, and the lack of effective treatment approaches for patients with ultra-high-risk risk cytogenetics. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think there are still very significant unmet needs for myeloma patients. Obviously the treatment paradigm is improving all of the time. There are several things that still concern me.
I think first of all patients are still being diagnosed too late when the myeloma has done significant damage. So delayed diagnosis, number one unmet need...
I think there are still very significant unmet needs for myeloma patients. Obviously the treatment paradigm is improving all of the time. There are several things that still concern me.
I think first of all patients are still being diagnosed too late when the myeloma has done significant damage. So delayed diagnosis, number one unmet need.
I think we need to take thalidomide out of the treatment pathway because it is associated with high rates of neuropathy and we should be using Dara-VRd rather than Dara-VTd because we know that combination of Velcade and Thalidomide are very neurotoxic. I think so those are two unmet needs.
I think the third big unmet need is patients with ultra high risk cytogenetics more than two abnormalities or two or more abnormalities and even with improvements in conventional therapy those patients still don’t do very well.
So my three big unmet needs are we need to make diagnosis more rapidly, we need to get rid of thalidomide from Daro-VTd and replace it with Revlimid, and we need to have a stylized treatment regime for patients with high-risk cytogenetics.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Johnson & Johnson, Amgen, Sanofi, Bristol Myers Squibb, Takeda, Pfizer, Menarini: Honoraria for advisory boards/speaking; Onyx, Bristol Myers Squibb, Takeda: Research Funding.
